CAPR vs. MBX
CAPR (Capricor Therapeutics, Inc.) and MBX (MBX Biosciences, Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, CAPR returned 119.02% vs 242.43% for MBX. At a 0.18 correlation, their price movements are largely independent.
Performance
CAPR vs. MBX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CAPR achieves a -10.60% return, which is significantly lower than MBX's 12.59% return.
CAPR
- 1D
- 3.04%
- 1M
- -10.39%
- YTD
- -10.60%
- 6M
- -0.85%
- 1Y
- 119.02%
- 3Y*
- 75.54%
- 5Y*
- 42.12%
- 10Y*
- -3.11%
MBX
- 1D
- -4.67%
- 1M
- 9.43%
- YTD
- 12.59%
- 6M
- 18.92%
- 1Y
- 242.43%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
CAPR vs. MBX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
CAPR Capricor Therapeutics, Inc. | -10.60% | 109.13% | 230.14% |
MBX MBX Biosciences, Inc | 12.59% | 71.13% | -19.87% |
Correlation
The correlation between CAPR and MBX is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Sep 13, 2024 | 0.18 |
Fundamentals
CAPR:
$1.48B
MBX:
$1.65B
CAPR:
-$2.32
MBX:
-$2.30
CAPR:
0.01
MBX:
3.78
CAPR:
$0.00
MBX:
$0.00
CAPR:
-$42.41M
MBX:
-$160.00K
CAPR:
-$117.24M
MBX:
-$96.31M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CAPR vs. MBX — Risk / Return Rank
CAPR
MBX
CAPR vs. MBX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Capricor Therapeutics, Inc. (CAPR) and MBX Biosciences, Inc (MBX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CAPR | MBX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.50 | ||
| Sortino ratioReturn per unit of downside risk | +1.11 | ||
| Omega ratioGain probability vs. loss probability | 1.60 | 1.39 | +0.22 |
| Calmar ratioReturn relative to maximum drawdown | 1.36 | 6.19 | -4.83 |
| Martin ratioReturn relative to average drawdown | 2.70 | 11.83 | -9.13 |
Loading charts...
Drawdowns
CAPR vs. MBX - Drawdown Comparison
The maximum CAPR drawdown since its inception was -99.97%, which is greater than MBX's maximum drawdown of -77.71%. Use the drawdown chart below to compare losses from any high point for CAPR and MBX.
Loading charts...
Drawdown Indicators
| CAPR | MBX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.97% | -77.71% | -22.26% |
Max Drawdown (1Y)Largest decline over 1 year | -62.84% | -37.60% | -25.24% |
Max Drawdown (3Y)Largest decline over 3 years | -79.08% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -79.08% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -97.89% | — | — |
Current DrawdownCurrent decline from peak | -99.21% | -17.69% | -81.52% |
Average DrawdownAverage peak-to-trough decline | -90.24% | -34.85% | -55.39% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.49% | 19.65% | +15.84% |
Volatility
CAPR vs. MBX - Volatility Comparison
The current volatility for Capricor Therapeutics, Inc. (CAPR) is 14.14%, while MBX Biosciences, Inc (MBX) has a volatility of 24.53%. This indicates that CAPR experiences smaller price fluctuations and is considered to be less risky than MBX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CAPR | MBX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.14% | 24.53% | -10.39% |
Volatility (6M)Calculated over the trailing 6-month period | 49.08% | 60.13% | -11.05% |
Volatility (1Y)Calculated over the trailing 1-year period | 384.48% | 135.18% | +249.30% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 189.99% | 119.14% | +70.85% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 179.76% | 119.14% | +60.62% |
Dividends
CAPR vs. MBX - Dividend Comparison
Neither CAPR nor MBX has paid dividends to shareholders.
Financials
CAPR vs. MBX - Financials Comparison
This section allows you to compare key financial metrics between Capricor Therapeutics, Inc. and MBX Biosciences, Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CAPR and MBX have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MBX has higher volatility (24.53%) compared to CAPR (14.14%). In terms of maximum drawdown, CAPR dropped -99.97% vs MBX's -77.71%.
MBX currently has the higher Sharpe Ratio (1.72 vs 0.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CAPR and MBX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer